Comparative Pharmacology
Head-to-head clinical analysis: METRONIDAZOLE IN PLASTIC CONTAINER versus SOLOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRONIDAZOLE IN PLASTIC CONTAINER versus SOLOSEC.
METRONIDAZOLE IN PLASTIC CONTAINER vs SOLOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
After intracellular reduction, metronidazole and its metabolites interact with DNA leading to inhibition of nucleic acid synthesis and cell death. It is active against anaerobic bacteria and protozoa.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
500 mg IV every 8 hours or 7.5 mg/kg IV every 6 hours (loading dose 15 mg/kg) for most anaerobic infections.
2 g orally as a single dose for trichomoniasis.
None Documented
None Documented
8 hours (range 6-12 hours) in adults with normal hepatic function; prolonged to 15-30 hours in severe liver disease
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (<5%)
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Category A/B
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic